Case Reports in Oncology
Published: October 2009
Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study GroupWada N.a · Kohara M.a · Ogawa H.d · Sugiyama H.b · Fukuhara S.e · Tatsumi Y.f · Kanamaru A.f · Hino M.g · Kanakura Y.c · Morii E.a · Aozasa K.aDepartments of aPathology, bFunctional Diagnostic Science and cHematology and Oncology, Osaka University Graduate School of Medicine, Suita, dDepartment of Internal Medicine, Hyogo College of Medicine, Nishinomiya, eFirst Department of Internal Medicine, Kansai Medical University, Moriguchi, fDepartment of Hematology, Kinki University School of Medicine, Sayama, and gDepartment of Clinical Hematology and Diagnostics, Osaka City University Graduate School of Medicine, Osaka, Japan
Katsuyuki Aozasa, MD Department of Pathology (C3), Osaka University Graduate School of Medicine 2-2 Yamadaoka, Suita, Osaka 565-0871 (Japan) Tel. +81 6 6879 3710, Fax +81 6 6879 3713, E-Mail aozasa@molpath.med.osaka-u.ac.jp |
|
Abstract
Change of CD20 expression was examined in cases of diffuse large B-cell lymphoma (DLBCL). CD20 expression after treatment with anti-CD20 antibody (rituximab, Rx) for DLBCL was examined in 23 cases who received serial biopsy by immunohistochemistry (IHC) and flow cytometry (FCM). CD20– by IHC and/or FCM was defined as CD20–. Four cases were CD20– at initial biopsy but became CD20+ after chemotherapy with Rx (CH-R) (group A). Recurrent tumors in three group A cases became resistant to CH-R. Initial and recurrent tumors were CD20+ before and after CH-R in 17 cases (group B). Tumors before CH-R were CD20– in two cases (group C) and continued to be CD20– in one and turned CD20+ in the other with survival time after the relapse of 8 and 23 months, respectively. Evaluation of CD20 expression with immunohistochemical and flow cytometric methods is used for the prediction of responsiveness of relapsed DLBCL for CH-R.
© 2009 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: October 21, 2009
Issue release date: September – December
Number of Print Pages: 9
Number of Figures: 2
Number of Tables: 2
eISSN: 1662-6575 (Online)
For additional information: https://www.karger.com/CRO
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
